CY1113218T1 - Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας - Google Patents

Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας

Info

Publication number
CY1113218T1
CY1113218T1 CY20111100383T CY111100383T CY1113218T1 CY 1113218 T1 CY1113218 T1 CY 1113218T1 CY 20111100383 T CY20111100383 T CY 20111100383T CY 111100383 T CY111100383 T CY 111100383T CY 1113218 T1 CY1113218 T1 CY 1113218T1
Authority
CY
Cyprus
Prior art keywords
amino acid
proteins
hybrid
nacterium
bilateral
Prior art date
Application number
CY20111100383T
Other languages
Greek (el)
English (en)
Inventor
Mariagrazia Pizza
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113218(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1113218T1 publication Critical patent/CY1113218T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20111100383T 2001-09-06 2011-04-15 Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας CY1113218T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121591.2A GB0121591D0 (en) 2001-09-06 2001-09-06 Hybrid and tandem expression of neisserial proteins
EP02777592A EP1423419B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins

Publications (1)

Publication Number Publication Date
CY1113218T1 true CY1113218T1 (el) 2016-04-13

Family

ID=9921633

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100383T CY1113218T1 (el) 2001-09-06 2011-04-15 Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
CY20151101166T CY1117065T1 (el) 2001-09-06 2015-12-22 Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151101166T CY1117065T1 (el) 2001-09-06 2015-12-22 Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων

Country Status (18)

Country Link
US (6) US8980277B2 (enExample)
EP (4) EP2327719B1 (enExample)
JP (4) JP4511832B2 (enExample)
CN (2) CN100390196C (enExample)
AT (1) ATE496063T1 (enExample)
AU (2) AU2002339217B2 (enExample)
BR (1) BR0212363A (enExample)
CA (1) CA2459816C (enExample)
CY (2) CY1113218T1 (enExample)
DE (1) DE60238993D1 (enExample)
DK (3) DK1423419T3 (enExample)
ES (3) ES2523365T3 (enExample)
GB (1) GB0121591D0 (enExample)
MX (2) MXPA04002216A (enExample)
NZ (3) NZ537976A (enExample)
PT (3) PT1423419E (enExample)
RU (2) RU2475495C2 (enExample)
WO (1) WO2003020756A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941567D1 (de) * 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP2270174A1 (en) * 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1412381B1 (en) 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2004014417A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
SI2353608T1 (sl) * 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic Proteínas de superfície de neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2540896C (en) * 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0415160D0 (en) * 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
ES2532946T3 (es) * 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
NZ593674A (en) * 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
CN102711814A (zh) 2009-04-30 2012-10-03 奥克兰儿童医院及研究中心 一种嵌合h因子结合蛋白(fhbp)及其使用方法
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
JP5363381B2 (ja) * 2010-03-09 2013-12-11 パナソニック株式会社 プラズマディスプレイパネル
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
CN110845585A (zh) 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
CN102028941B (zh) * 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
WO2013009739A2 (en) * 2011-07-11 2013-01-17 Uvic Industry Partnerships Inc. Soluble treponema pallidum protein tp0453,tp0453-tp0326 fusion protein, and use in syphilis diagnosis
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EA201690056A8 (ru) * 2013-08-02 2017-07-31 Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CN119613509A (zh) 2014-07-23 2025-03-14 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3035320A1 (en) * 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
KR102871663B1 (ko) 2019-09-27 2025-10-16 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196056B1 (en) * 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
DE3622221A1 (de) 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
BR9007917A (pt) * 1989-12-14 1992-10-20 Ca Nat Research Council Vacina aperfeicoada de conjugado polissacaridico meningogocico
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2105382C (en) 1991-03-14 1999-01-19 Neil Goldstein Recombinant hybrid porin epitopes
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
RU2074728C1 (ru) * 1993-01-03 1997-03-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова РАМН Липополисахарид из neisseria meningitidis, обладающий протективными и иммуногенными свойствами
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6165747A (en) 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
DE69841807D1 (de) * 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
ATE352624T1 (de) 1997-11-21 2007-02-15 Serono Genetics Inst Sa Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
ATE375393T1 (de) * 1998-01-30 2007-10-15 Asubio Pharma Co Ltd Verfahren zur herstellung eines peptids mittels eines hilfspeptids
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
DE69937419T2 (de) 1998-05-01 2008-07-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria Meningitidis Antigene und Zusammenstellungen
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
CA2347849C (en) * 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2000056359A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
US7368261B1 (en) 1999-04-30 2008-05-06 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
BR0107857A (pt) 2000-01-25 2002-10-29 Univ Queensland Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
US20040167058A1 (en) * 2000-06-29 2004-08-26 Colgate-Palmolive Company Multi-phase clear fabric softening composition
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1412381B1 (en) 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
SI2353608T1 (sl) 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
MXPA05011110A (es) 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
CA2540896C (en) 2003-10-02 2015-06-02 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100150912A1 (en) 2007-04-11 2010-06-17 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles

Also Published As

Publication number Publication date
DE60238993D1 (de) 2011-03-03
NZ532115A (en) 2005-04-29
DK2360176T3 (en) 2015-12-14
US20140294886A1 (en) 2014-10-02
CY1117065T1 (el) 2017-04-05
CN101260148A (zh) 2008-09-10
RU2475495C2 (ru) 2013-02-20
PT2360176E (pt) 2016-01-11
EP2327719A1 (en) 2011-06-01
ES2357503T3 (es) 2011-04-27
AU2008234959A1 (en) 2008-11-13
EP2829549A3 (en) 2015-06-03
NZ537976A (en) 2008-03-28
ES2556770T3 (es) 2016-01-20
US8980277B2 (en) 2015-03-17
PT2327719E (pt) 2014-12-02
US20120195919A1 (en) 2012-08-02
US9011869B2 (en) 2015-04-21
GB0121591D0 (en) 2001-10-24
CN100390196C (zh) 2008-05-28
CA2459816C (en) 2014-06-10
MXPA04002216A (es) 2005-02-17
DK1423419T3 (da) 2011-04-04
EP1423419B1 (en) 2011-01-19
AU2002339217B2 (en) 2008-09-04
BR0212363A (pt) 2004-08-10
DK2327719T3 (da) 2014-11-03
EP2360176A2 (en) 2011-08-24
JP4511832B2 (ja) 2010-07-28
US8840907B2 (en) 2014-09-23
ATE496063T1 (de) 2011-02-15
US20150273044A1 (en) 2015-10-01
MX336118B (es) 2016-01-08
PT1423419E (pt) 2011-03-10
EP2360176B1 (en) 2015-10-21
EP2360176A3 (en) 2012-01-18
CN101260148B (zh) 2012-05-09
NZ547145A (en) 2008-06-30
US20050222385A1 (en) 2005-10-06
JP2005508156A (ja) 2005-03-31
EP1423419A2 (en) 2004-06-02
JP2014051497A (ja) 2014-03-20
RU2339646C2 (ru) 2008-11-27
CN1582297A (zh) 2005-02-16
RU2004110230A (ru) 2005-04-20
CA2459816A1 (en) 2003-03-13
US20110250223A1 (en) 2011-10-13
JP2010252807A (ja) 2010-11-11
WO2003020756A2 (en) 2003-03-13
RU2008122435A (ru) 2009-12-10
WO2003020756A3 (en) 2003-11-20
EP2327719B1 (en) 2014-08-20
US9056075B2 (en) 2015-06-16
JP2005350486A (ja) 2005-12-22
JP5542276B2 (ja) 2014-07-09
ES2523365T3 (es) 2014-11-25
US20180169210A1 (en) 2018-06-21
EP2829549A2 (en) 2015-01-28
AU2008234959B2 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20063026L (no) Antistoffer
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
CY1111283T1 (el) Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
ATE184052T1 (de) Gdf-1 und uog1 proteine
CY1110360T1 (el) Τροποποιημενος παραγοντας viii
CY1109664T1 (el) Πρωτεϊνες δεσμευσεως ιντερλευκινης-18, η παρασκευη και η χρηση τους
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EA200000144A1 (ru) Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
DE69915320D1 (de) Immunoglobulin-bindende proteine
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
DE60335726D1 (de) Chromoprotein und fluoroproteine
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
NO970113D0 (no) Kollagenbindende protein eller polypeptid
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen